Shares of Singapore Institute of Advanced Medicine surged nearly 40% in recent trading.
Singapore Institute of Advanced Medicine (SGX:9G2) revealed that PwC, its external auditor issued a disclaimer of opinion on the company's financial statements for the fiscal year ended June 30, a filing with the Singapore Exchange said on Wednesday.
The company had reported a loss of SG$37.4 million after tax for the period and the auditor has highlighted doubt on its ability to continue as a going concern.
Net cash used in operations amounts to SG$12.9 million while liabilities have exceeded current assets by around SG$7.9 million.
The medical services company relies on a subsidiary that represents 87% of its total assets, which booked a loss after tax of around SG$21.1 million.
The external auditor said the company would require to make significant adjustments to its asset valuations and liability classifications.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。